10-Q · March 10, 2026
BriaCell reported no revenue and a net loss attributable to BriaCell of $7,221,820 for the quarter ended January 31, 2026 (vs. $6,291,420 in prior-year quarter). Cash increased materially to $29,903,628 following net…
Earnings analysis · 10-Q
BCTX earnings analysis
Filed June 9, 2026 · Our reading of the company's report
The latest report
BriaCell Therapeutics reported no revenue for Q2 2026 alongside a diluted EPS loss of $0.99, showing a mitigating trend from a loss of $16.42 in Q2 2025. The company significantly increased its research and development…
Read full summary
BriaCell Therapeutics reported no revenue for Q2 2026 alongside a diluted EPS loss of $0.99, showing a mitigating trend from a loss of $16.42 in Q2 2025. The company significantly increased its research and development spending to support ongoing clinical studies, with cash reserves of $29.9 million remaining strong post-public offering. Despite these improvements, the company continues to grapple with high operating losses and substantial reliance on future financing.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.99
What stood out
-
Improvement in EPS
Diluted EPS loss improved to -$0.99 from -$16.42 a year ago.
-
Strong Cash Reserves
Cash and cash equivalents amount to $29.9 million post recent financing.
-
Increased Clinical Investment
R&D expenses rose to $5.97 million from $4.81 million year-over-year.
-
Positive Cash Flow from Financing
Generated approximately $30 million in gross proceeds from a public offering.
-
Expanded Clinical Activities
Clinical trial expenses up to $4.35 million, driven by pivotal Phase 3 study of Bria-IMT.
-
Working Capital Improvement
Working capital increased to $21.8 million from $15.9 million year-over-year.
What to watch
-
Continued Operating Losses
Net loss for Q2 2026 was $7.24 million, up from $6.22 million year-over-year.
-
High Cash Burn Rate
Operating cash flow used rose to $22.69 million for the nine-month period.
-
Reliance on Future Financing
Company's ability to continue as a going concern is increasingly uncertain.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · December 11, 2025
BriaCell reported no revenue and a wider quarterly net loss of $8,278,328 for the three months ended October 31, 2025, versus $5,829,276 in the prior-year quarter, driven by a sharp increase in R&D spending as the…
10-Q · June 16, 2025
BriaCell reported a Q3 net loss of $6,224,929 (BriaCell attributable loss $6,126,902) and diluted EPS of $(1.64), reversing a prior-year quarterly income of $1,692,242 (EPS $1.61). Cash improved sharply to $12,460,253…
10-Q · December 16, 2024
BriaCell reported a net loss of $5,829,276 (net loss per share – basic $0.22) for the three months ended October 31, 2024, an improvement in operating loss to $5,152,832 from $8,503,028 a year earlier. The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.